Back to Search
CARLOS OLIVA, M.D.
M.D.
Family Medicine Physician
NPI: 1891882239IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
A40155(CA)
CMS Specialties
PrimaryGENERAL PRACTICE
Education
OTHER
Class of 1978
Research & Publications (20)
SNOM images of X-ray radiographs at nano-scale stored in a thin layer of lithium fluoride.
PMID 18331500·J Microsc·2008
8-other
A quantum mechanics/molecular mechanics study of the reaction mechanism of the hepatitis C virus NS3 protease with the NS5A/5B substrate.
PMID 17094110·Proteins·2007
8-other
Electron paramagnetic resonance and ultraviolet/visible study of compounds I and II in the horseradish peroxidase-H(2)O(2)-silk fiber reaction system.
PMID 12736077·Spectrochim Acta A Mol Biomol Spectrosc·2003
8-other
Spin glass formation in La0.9Sr0.1CoO3 catalyst for flameless combustion of methane.
PMID 10727147·Spectrochim Acta A Mol Biomol Spectrosc·2000
4-observational
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
PMID 19620495·J Clin Oncol·2009
2-rct
[Negative-pressure wound therapy versus standard wound dressing in the treatment of diabetic foot amputation. A randomised controlled trial].
PMID 19616774·Cir Esp·2009
4-observational
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
PMID 19417026·Clin Cancer Res·2009
8-other
CD14-Mac-1 interactions in Bacillus anthracis spore internalization by macrophages.
PMID 19666536·Proc Natl Acad Sci U S A·2009
7-preclinical
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
PMID 19228746·Clin Cancer Res·2009
3-trial
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
PMID 18955454·J Clin Oncol·2008
3-trial
Nanoscale uniform self-assembled monolayers of fluorescent zinc(II) complexes on the Si(100) surface.
PMID 19044977·J Chem Phys·2008
8-other
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
PMID 18667394·Ann Oncol·2008
3-trial
The integrin Mac-1 (CR3) mediates internalization and directs Bacillus anthracis spores into professional phagocytes.
PMID 18216258·Proc Natl Acad Sci U S A·2008
7-preclinical
Bilateral ovarian pregnancy after intrauterine insemination and controlled ovarian stimulation.
PMID 18394622·Fertil Steril·2008
5-case
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
PMID 18501066·Clin Breast Cancer·2008
4-observational
Temporal and spatial expression of Drosophila DLGS97 during neural development.
PMID 18501681·Gene Expr Patterns·2008
7-preclinical
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
PMID 18621618·Clin Breast Cancer·2008
3-trial
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
PMID 19047115·Clin Cancer Res·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1070 S SANTA FE AVE STE 9
VISTA, CA 92084 - Phone
- (760) 941-7050
Quick Facts
- NPI
- 1891882239
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 48
- Publications
- 20
Are you this provider?
Claim Your Profile